RecruitingNCT06864221

Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma

Correlation Between Plasma Sphingolipid Metabolites and the Efficacy of Radiotherapy in Hepatocellular Carcinoma

Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

260 participants

Start Date

Sep 1, 2024

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma Radiotherapy Treatment Outcome Biomarkers Sphingolipids

Summary

Plasma contains a variety of metabolites, among which sphingolipids, including ceramide, sphingosine, and sphingosine-1-phosphate, serve as important intracellular second messengers and are involved in various cellular signaling pathways, such as apoptosis. We hypothesize that plasma sphingolipid levels may be associated with the efficacy of radiotherapy for liver cancer. This study will utilize LC-MS/MS technology for qualitative and quantitative analysis of plasma sphingolipids in liver cancer patients undergoing radiotherapy. Clinical data related to patient prognosis will also be collected to investigate the correlation between plasma sphingolipid levels and the therapeutic efficacy of liver cancer radiotherapy. The aim is to establish the clinical diagnostic significance of plasma sphingolipid levels in predicting the efficacy of liver cancer radiotherapy, providing new insights to enhance the effectiveness of radiotherapy in liver cancer treatment.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is measuring certain fat-like molecules called sphingolipids in the blood of people with liver cancer who are receiving radiation therapy, to see if these molecules can predict how well the radiation will work. **You may be eligible if...** - You are between 18 and 80 years old - You have been clinically diagnosed with primary liver cancer - Your doctor has recommended radiotherapy as part of your treatment - You are expected to survive for more than 3 months **You may NOT be eligible if...** - You stopped or did not complete your planned radiotherapy - You have a second, unrelated cancer - You have uncontrolled metabolic diseases like uncontrolled diabetes or severe obesity - You have serious heart or lung conditions that could affect your treatment or the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.